CLINICAL TRIALS AND OBSERVATIONS Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
نویسندگان
چکیده
1 Service d’Hematologie Clinique, Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris (AP-HP), Université Paris 13, Bobigny, France; 2Inserm U848, Villejuif, France; 3Departement d’Informatique Medicale, Hôpital Saint Louis AP-HP, Université Paris 7, Paris, France; 4Service d’Hematologie Adulte, Hôpital Saint Louis AP-HP, Université Paris 7, Paris, France; 5Service d’Hematologie Clinique, Hôpital Huriet, Centre Hospitalier Universitaire (CHU) de Lille, Université Lille 2, Lille, Franc; 6Service d’Oncologie-hématologie, Groupe Hospitalier Intercommunal, Montfermeil, France; 7Service d’Hematologie clinique, Hôpital Purpan, CHU de Toulouse, Université Paul Sabatier, Toulouse, France; 8Service d’Hematologie Clinique, Hôptital Cochin APHP, Université Paris 5, Paris, France; 9Service d’Hematologie Clinique, Hôpital l’Archet, Université de Nice, Nice, France; 10Service d’Hematologie Clinique, Hotel Dieu, Université de Nantes, Nantes, France; 11Service d’Hematologie, Centre Hospitalier de Perpignan, Perpignan, France; 12Laboratoire d’Hematologie, Hôpital Avicenne, Université Paris 13, Bobigny, France; 13Service d’Hematologie, Hôpital Bretonneau, Université de Tours, Tours, France; 14Service d’Hematologie, Hôpital Dupuytren, Université de Limoges, Limoges, France; 15Service d’Hematologie Adulte, Hôpital Necker AP-HP, Université Paris 5, Paris, France; 16Service d’Hematologie, Centre Hospitalier Sud Francillien, Corbeil Essonne, France; and 17Centre d’Investigation Clinique, Hôpital Saint Louis AP-HP, Université Paris 7, Paris, France
منابع مشابه
The renaissance of interferon therapy for the treatment of myeloid malignancies.
IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy is likely the consequence of its broad range of biologic activities, including direct effects on malignant cells, enhancement of anti-tumor immune responses, induction of proapoptotic genes, inhibition of angiogenesis, and promotion of the cycling of dormant malignant stem cells. Because of the recent...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/ myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and ch...
متن کاملA Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
5-Aza-2'-deoxycytidine (5-AZA-CdR, decitabine, Dacogen®) and 5-azacytidine (5-AC, Vidaza®) are epigenetic agents that have been approved for the clinical treatment of the hematological malignancy myelodysplastic syndrome (MDS) and are currently under clinical evaluation for the treatment of acute myeloid leukemia (AML). Most investigators currently classify 5-AZA-CdR and 5-AC as inhibitors of D...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements
Danielle Sainty, Vincenzo Liso, Angelo Cantù-Rajnoldi, David Head, Marie-Joëlle Mozziconacci, Christine Arnoulet, Laurence Benattar, Susanna Fenu, Marco Mancini, Eliane Duchayne, François-Xavier Mahon, Norma Gutierrez, Françoise Birg, Andrea Biondi, David Grimwade, Marina Lafage-Pochitaloff, Anne Hagemeijer, and Georges Flandrin, on behalf of Groupe Français d’Hématologie Cellulaire, Groupe Fra...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
The survival of patients with aggressive non-Hodgkin lymphoma (NHL) is increasing, but the incidence of secondary cancer and late toxicity is poorly defined for those treated with cyclophosphamidehydroxydaunomycin/doxorubicin-Oncovin-prednisone (CHOP)–like chemotherapy. From February 1984 to January 1998, 2837 patients with aggressive NHL received the control-arm chemotherapy adriamycin-cycloph...
متن کامل